GlassScriptPhysician profile
Roman Perez-Soler
NPI 1316027808
$23,847.74
in general payments reported to CMS, 2019-2025
4 companies · $3,900 in 2025
The $3,900 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,648 · 2020: $1,500 · 2021: $3,500 · 2022: $600 · 2023: $5,100 · 2024: $3,600 · 2025: $3,900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $13K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $12,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13,200.00 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $5,406.28 | 2019 | |
| Merck Sharp & Dohme LLC | $5,114.68 | 2019-2021 | |
| Genentech USA, INC. | $126.78 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roman Perez-Soler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.